Combination therapies using anti-HER2 monoclonal antibodies and chemotherapeutic agents are the major approaches for treating HER2 positive breast cancer, especially for metastatic cancer [105]. This evidence concerns the gene ERBB2 and metastatic malignant neoplasm.